KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. PMID 37396800 · EClinicalMedicine · 2023-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A protocol for a pilot study to assess the feasibility of a randomised clinical trial of perioperative intravenous lidocaine on colorectal cancer outcome after surgery (FLICOR trial). PMID 37387798 · BJA Open · 2023-Jun 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Operational Challenges of an Asia-Pacific Academic Oncology Clinical Trial. PMID 37364220 · JCO Glob Oncol · 2023-Jun The record describes operational challenges of running a phase III randomized trial (ASCOLT) studying aspirin in colorectal cancer, but it is not a primary or secondary result report of the trial's efficacy outcomes. The abstract focuses on trial conduct issues and does not report any time-to-event efficacy data (e.g., OS, DFS), Kaplan-Meier curves, or hazard ratios. Therefore, it does not meet the criteria for a formal result report with a primary/key secondary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II Trial on the Feasibility of Single-Dose Intraoperative Intraperitoneal Carboplatin in Advanced Epithelial Ovarian Cancer Following Optimal Cytoreductive Surgery. PMID 37359925 · Indian J Surg Oncol · 2023-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Impact of general anaesthesia on breast cancer survival: a 5-year follow up of a pragmatic, randomised, controlled trial, the CAN-study, comparing propofol and sevoflurane. PMID 37333664 · EClinicalMedicine · 2023-Jun The study is an oncology human randomized trial with a primary overall survival endpoint and reports Kaplan-Meier/HR results. However, the intervention compares two anesthetic techniques (propofol vs. sevoflurane), which are not considered 'drug-containing' in the context of oncology systemic therapy. The trial phase is not explicitly stated as Phase III or equivalent, and the metadata does not provide sufficient evidence to establish a definitive phase. Therefore, it does not meet the requirement for a drug-containing intervention in a Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. PMID 37287870 · EClinicalMedicine · 2023-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer. PMID 37285718 · ESMO Open · 2023-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study. PMID 37285716 · ESMO Open · 2023-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial. PMID 37270871 · ESMO Open · 2023-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results. PMID 37260158 · Cancer Med · 2023-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding (UCON): a randomised controlled phase III trial. PMID 37251622 · EClinicalMedicine · 2023-Jun The study is a randomized phase III trial with a drug intervention and original results, but it is not an oncology study (focused on heavy menstrual bleeding/uterine fibroids) and does not have a time-to-event efficacy endpoint (e.g., OS, PFS).
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Design and methods of a translational, community-based, lifestyle weight management pilot intervention trial in breast cancer survivors with overweight or obesity. PMID 37250507 · Contemp Clin Trials Commun · 2023-Jun This is a single-arm pilot study protocol describing a lifestyle weight management intervention for breast cancer survivors. It lacks randomization, a specified advanced phase, a drug intervention, and a time-to-event efficacy endpoint. It is a protocol without definitive results, not an original result report of a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A nurse-led intervention in patients with newly diagnosed cancer and Type 2 diabetes: A pilot randomized controlled trial feasibility study. PMID 37212484 · Cancer Med · 2023-Jun The study is a pilot/feasibility RCT in an oncology setting, but it is not a definitive Phase III/IIIb or Phase II/III trial, the drug (metformin) is not the primary intervention (nurse-led education is), and the primary outcome is feasibility/recruitment, not a time-to-event efficacy endpoint like OS/PFS/DFS with Kaplan-Meier or HR.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. PMID 37210099 · Lancet Neurol · 2023-Jun The trial is for Huntington's disease, not oncology. The primary efficacy endpoint is a change in chorea symptom score (UHDRS TMC), which is not a time-to-event outcome (OS, PFS, DFS, etc.) or Kaplan-Meier analysis.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluation the benefits of additional radiotherapy for gastric cancer patients after D2 resection using CT based radiomics. PMID 37188857 · Radiol Med · 2023-Jun The study is a retrospective radiomics analysis for predicting survival in gastric cancer patients who received chemotherapy or chemoradiation, not a randomized controlled trial comparing therapeutic interventions. The randomization described is for data splitting, not trial randomization. No explicit Phase III/IIIb or Phase II/III trial evidence is provided.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of HPV self-collection kits on cervical cancer screening uptake among under-screened women from low-income US backgrounds (MBMT-3): a phase 3, open-label, randomised controlled trial. PMID 37182529 · Lancet Public Health · 2023-Jun The trial meets criteria for human, randomized, phase 3, original-result oncology study, but it is excluded because: 1) The primary efficacy endpoint is 'cervical cancer screening uptake' (a binary proportion at 6 months), not a time-to-event endpoint like OS, PFS, DFS, etc., nor is it analyzed with Kaplan-Meier or reported as a hazard ratio. 2) The intervention is a screening diagnostic tool (HPV self-collection kit) with scheduling assistance, not a drug-containing therapeutic intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial. PMID 37168818 · Contemp Clin Trials Commun · 2023-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group. PMID 37167992 · Lancet Haematol · 2023-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Ravulizumab: A Review in Generalised Myasthenia Gravis. PMID 37166620 · Drugs · 2023-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles. PMID 37162707 · Invest New Drugs · 2023-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors. PMID 37140602 · Cancer Chemother Pharmacol · 2023-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Establishment and validation of a prognostic nomogram for postoperative patients with gastric cardia adenocarcinoma: A study based on the Surveillance, Epidemiology, and End Results database and a Chinese cohort. PMID 37132269 · Cancer Med · 2023-Jun The study is an original prognostic nomogram development and validation study for gastric cardia adenocarcinoma using retrospective registry (SEER) and institutional data. It analyzes clinicopathological variables, not a drug intervention. It is not a randomized trial of a therapeutic agent (despite 'Randomized Controlled Trial' in publication types, the randomization was for data splitting, not intervention assignment). It lacks a drug-containing intervention and a comparative trial phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial. PMID 37121015 · Thromb Res · 2023-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Laparo-endoscopic single-site versus conventional laparoscopic surgery for early-stage endometrial cancer: A randomized controlled non-inferiority trial. PMID 37105060 · Gynecol Oncol · 2023-Jun 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India. PMID 37093266 · Cancer Chemother Pharmacol · 2023-Jun Study meets criteria for oncology, human, randomized, Phase 3, and drug intervention, but the primary efficacy endpoint is ORR (a response rate), not a time-to-event endpoint (OS, PFS, DFS, EFS, RFS, TTP). No time-to-event signal is present in the abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial. PMID 37080000 · Leuk Res · 2023-Jun The study does not meet the inclusion criteria because it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR), and the intervention is not a drug-containing intervention. Additionally, the phase is not explicitly established as Phase III or Phase II/III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis. PMID 37075698 · ESMO Open · 2023-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Statistical considerations of designs for single-arm proof-of-concept oncology trial with time-to-event endpoint. PMID 37068588 · Contemp Clin Trials · 2023-Jun The record is a methodological paper describing statistical designs for single-arm oncology trials, not a report of a completed randomized Phase II/III or Phase III trial with drug intervention and efficacy results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial. PMID 37062416 · Ann Oncol · 2023-Jun The record describes a randomized trial with drug interventions and a time-to-event efficacy endpoint (dDFS). However, the trial phase is not explicitly stated as Phase III, IIIb, or Phase II/III in the provided metadata (title, abstract, publication types, MeSH, keywords). The abstract refers to it as a 'neoadjuvant randomized trial' but does not specify the formal phase. Therefore, the 'phase3_or_definitive' criterion cannot be established.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. PMID 37061619 · Breast Cancer Res Treat · 2023-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy of smartphone applications to help cancer patients quit smoking: Protocol of the Quit2Heal randomized controlled trial. PMID 37040817 · Contemp Clin Trials · 2023-Jun The record is a protocol for a randomized trial of a smartphone app for smoking cessation in cancer patients. It is not a drug intervention, not a definitive phase trial, and the primary endpoint is not a time-to-event outcome. It is a protocol without results, thus ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The impact of COVID-19 on a large pragmatic clinical trial embedded in primary care. PMID 37031794 · Contemp Clin Trials · 2023-Jun The record is not an oncology study; it is a pragmatic trial of diuretics for cardiovascular outcomes. It reports on operational impact of COVID-19, not formal efficacy results with time-to-event endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trials. PMID 37028684 · J Clin Epidemiol · 2023-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes. PMID 37017631 · Clin Pharmacol Ther · 2023-Jun The study is a randomized, Phase III clinical trial with a drug intervention (molnupiravir) and reports original results. However, the study addresses COVID-19, which is not a human malignant neoplasm (cancer), and the primary efficacy endpoint is hospitalization risk (logistic regression, odds ratio), not a time-to-event outcome (e.g., OS, PFS, DFS) analyzed with Kaplan-Meier or hazard ratios.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence? PMID 37012085 · Rev Neurol (Paris) · 2023-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial. PMID 37003098 · Eur J Cancer · 2023-Jun The record describes a biomarker analysis (sTKa) from the Phase IIIb BioItaLEE trial. While it is an oncology trial with a drug intervention and time-to-event endpoint (PFS), the report is a secondary/biomarker analysis, not the primary efficacy report of the randomized trial. Randomization is not explicitly mentioned in the abstract, though it is implied by the Phase IIIb designation. The core finding is about a biomarker's prognostic value, not the primary comparison of the randomized treatment arms.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Predicting Post-hepatectomy Liver Failure Preoperatively for Child-Pugh A5 Hepatocellular Carcinoma Patients by Liver Stiffness. PMID 36977863 · J Gastrointest Surg · 2023-Jun The record is a retrospective, observational study evaluating a diagnostic predictive model for post-hepatectomy liver failure (a surgical complication) in hepatocellular carcinoma patients. Although the publication type is listed as 'Randomized Controlled Trial', the methods describe a retrospective review where patients were randomly divided into training/validation cohorts for statistical modeling, not a randomized intervention trial. There is no drug intervention; the study is non-drug only. The endpoint (PHLF) is a postoperative complication, not a time-to-event oncology efficacy endpoint (e.g., OS, PFS). Therefore, it does not meet eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS). PMID 36967267 · Clin Colorectal Cancer · 2023-Jun The record describes a subgroup analysis of the SCOT study, which is a randomized adjuvant chemotherapy trial. While it reports DFS results and is a randomized trial with a drug intervention, the provided metadata does not explicitly confirm the trial phase as Phase III or definitive. Furthermore, the report focuses on a subgroup (tumor sidedness), not the primary trial result, making it ineligible as a primary report of a definitive randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
"Happy to close?" The relationship between surgical experience and incisional hernia rates following abdominal wall closure in colorectal surgery. PMID 36965056 · Colorectal Dis · 2023-Jun The record describes a randomized controlled trial (HART) in colorectal cancer surgery, but the intervention is surgical technique (closure method), not a drug. The primary endpoint is a binary outcome (incisional hernia rate), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, TTP) with Kaplan-Meier or HR analysis. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort requiring a drug-containing intervention and a primary/key secondary time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. PMID 36944848 · Breast Cancer Res Treat · 2023-Jun The record is eligible for inclusion as it reports an original, randomized, drug-intervention trial in human oncology with time-to-event efficacy endpoints. However, the trial phase (Phase II/III or Phase III/IIIb) is not explicitly stated in the provided metadata or abstract, preventing a definitive 'phase3_or_definitive' confirmation. Therefore, overall eligibility is set to null pending phase verification.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Development and validation of a prognostic nomogram for overall and disease-specific survival in patients with sarcomatoid urothelial carcinoma. PMID 36931981 · Urol Oncol · 2023-Jun The record is a prognostic nomogram development and validation study using retrospective SEER database data. While it is an oncology, human, randomized (patients randomly divided into training/validation cohorts), and time-to-event (OS, DSS) study, it is not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention. The randomization refers only to splitting the dataset for model development, not a clinical trial comparing interventions. No drug intervention is explicitly tested or reported as a primary/key secondary endpoint. Therefore, it does not meet the eligibility criteria for a drug-intervention efficacy trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tailored axillary surgery - A novel concept for clinically node positive breast cancer. PMID 36922305 · Breast · 2023-Jun This is an ongoing randomized controlled trial evaluating a surgical intervention (tailored axillary surgery vs. axillary lymph node dissection) with radiotherapy, not a drug-containing intervention. It is a surgical de-escalation study; the intervention is not pharmacological. While it meets criteria for oncology, human, randomized, and time-to-event endpoint, it fails the drug intervention requirement. The phase is also not definitively established as Phase III in the provided record.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial. PMID 36893780 · Lancet Respir Med · 2023-Jun The record describes a Phase 3 clinical trial in human oncology (NSCLC) with a time-to-event primary endpoint (5-year relapse-free survival). However, it is explicitly a single-arm trial, so it fails the randomized trial requirement. Furthermore, the intervention is a surgical procedure (segmentectomy), not a drug-containing intervention, which also excludes it.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial. PMID 36881786 · JCO Oncol Pract · 2023-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation. PMID 36880836 · Am J Hematol · 2023-Jun While the record describes a randomized trial with oncology, human, drug intervention, and time-to-event efficacy endpoints, the formal trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata or abstract. The deterministic review flagged phase evidence as unclear. Without explicit phase confirmation, the record cannot be deemed definitively eligible.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Extracorporeal Photopheresis as Graft-versus-Host Disease Prophylaxis: A Randomized Controlled Trial. PMID 36878428 · Transplant Cell Ther · 2023-Jun The study is an original result RCT in oncology patients with a time-to-event primary endpoint, but it does not meet the drug-intervention criterion as the intervention is a medical device/procedure (extracorporeal photopheresis). Additionally, the trial phase is not specified as Phase III or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Vincristine and dexamethasone pulses in addition to maintenance therapy among pediatric acute lymphoblastic leukemia (GD-ALL-2008): An open-label, multicentre, randomized, phase III clinical trial. PMID 36877527 · Am J Hematol · 2023-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data. PMID 36848009 · Rheumatol Ther · 2023-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. PMID 36822969 · Eur Urol · 2023-Jun 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Accurate tumor segmentation and treatment outcome prediction with DeepTOP. PMID 36813177 · Radiother Oncol · 2023-Jun The record describes a methodological study using data from a Phase III randomized trial to develop and validate a deep learning tool for tumor segmentation and predicting pathological complete response. While the underlying trial is a randomized Phase III oncology trial, this specific report does not present trial efficacy results with a time-to-event endpoint (e.g., OS, PFS). The endpoint reported is pathological complete response, a binary outcome, not a time-to-event endpoint. Additionally, no specific drug intervention is named; the abstract only mentions 'chemo/radiotherapy'. Therefore, it does not meet the criteria for inclusion as an original formal-result report with a primary/key secondary time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -